NZ601002A - Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture - Google Patents

Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture

Info

Publication number
NZ601002A
NZ601002A NZ601002A NZ60100209A NZ601002A NZ 601002 A NZ601002 A NZ 601002A NZ 601002 A NZ601002 A NZ 601002A NZ 60100209 A NZ60100209 A NZ 60100209A NZ 601002 A NZ601002 A NZ 601002A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical composition
vitamin
analogue
cosolvent
surfactant mixture
Prior art date
Application number
NZ601002A
Inventor
Karsten Petersson
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of NZ601002A publication Critical patent/NZ601002A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Provided is a topical pharmaceutical composition which is an oil-in-water-in-oil emulsion comprising the vitamin D analogue calcipotriol dissolved in a mixture of a non-ionic surfactant selected from the group consisting of polyoxyethylene glycol C6-C20 fatty acid glyceride, polyoxyethylene C8-C20 alkyl ethers or polysorbates and a lower alkanol such as ethanol, n-propanol and isopropanol together with a non-aqueous carrier such as paraffin. The topical pharmaceutical composition may be used in the treatment of dermal conditions, such as psoriasis.
NZ601002A 2009-12-22 2009-12-22 Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture NZ601002A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2009/000266 WO2011076206A1 (en) 2009-12-22 2009-12-22 Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture

Publications (1)

Publication Number Publication Date
NZ601002A true NZ601002A (en) 2014-09-26

Family

ID=44194970

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601002A NZ601002A (en) 2009-12-22 2009-12-22 Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture

Country Status (13)

Country Link
EP (1) EP2515912A4 (en)
JP (1) JP5548275B2 (en)
CN (1) CN102770143B (en)
AU (1) AU2009357263B2 (en)
BR (1) BR112012015447A2 (en)
CA (1) CA2785249A1 (en)
HK (1) HK1177695A1 (en)
IL (1) IL220513A (en)
MX (1) MX2012007227A (en)
NZ (1) NZ601002A (en)
RU (1) RU2500387C1 (en)
WO (1) WO2011076206A1 (en)
ZA (1) ZA201204619B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107643354B (en) * 2016-07-22 2022-02-01 重庆华邦胜凯制药有限公司 Separation and determination method of calcipotriol starting material A and related impurities
CN106265511A (en) * 2016-08-22 2017-01-04 江苏知原药业有限公司 A kind of calcipotriol betamethasone self-micro emulsion formulation of excellent performance
CN106265485A (en) * 2016-08-22 2017-01-04 江苏知原药业有限公司 A kind of calcipotriol compositions of improved stability
CN106344589B (en) * 2016-11-10 2019-11-26 江苏知原药业有限公司 A kind of Calcipotriol betamethasone composition of improved stability
CN108904445A (en) * 2018-08-06 2018-11-30 江苏知原药业有限公司 Its salts nano suspending liquid
US20230225970A1 (en) * 2020-08-26 2023-07-20 Canadian Nano Pharmaceutical Technology Inc. Nano-Emulsion Based Compositions, Methods for Their Preparation and Their Use in Delivery of Active Ingredients
CN115350151B (en) * 2022-09-29 2023-09-12 湖北欣泽霏药业有限公司 High-stability alfacalcidol liquid oral preparation and preparation method thereof
CN116473985A (en) * 2023-03-29 2023-07-25 暨南大学 Polyene antifungal pharmaceutical composition and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300763D0 (en) * 1993-01-15 1993-03-03 Leo Pharm Prod Ltd Chemical compound
JP3340310B2 (en) * 1996-03-28 2002-11-05 株式会社資生堂 Composite emulsion and method for producing the same
KR20010032892A (en) * 1997-12-09 2001-04-25 나가야마 오사무 Creams containing vitamin d3 derivatives
EP1051974A4 (en) * 1997-12-09 2001-09-12 Chugai Pharmaceutical Co Ltd Lotions containing vitamin d 3 derivatives
US5990100A (en) * 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
EP1178960B1 (en) * 1999-04-23 2003-11-05 Leo Pharma A/S Vitamin d analogues and their pharmaceutical use
JP2001025359A (en) * 1999-07-15 2001-01-30 Mitsubishi-Kagaku Foods Corp O/w/o type emulsion composition and its production
BRPI0613230A2 (en) * 2005-06-10 2011-01-04 Galderma Sa method for controlled release of a drug, method of administration, method of treating skin disorders, controlled release composition and use of a composition
CA2612408A1 (en) * 2005-06-15 2006-12-28 Apollo Pharmaceutical, Inc. Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis
FR2893847B1 (en) * 2005-11-30 2010-10-29 Galderma Sa SPRAY COMPOSITION COMPRISING VITAMIN D DERIVATIVE AND OILY PHASE
JP4913487B2 (en) * 2006-07-07 2012-04-11 ポーラ化成工業株式会社 Cosmetics characterized by a feeling of use
FR2909284B1 (en) * 2006-11-30 2012-09-21 Galderma Sa NOVEL VASELIN-FREE OINTMENTAL COMPOSITIONS COMPRISING VITAMIN D DERIVATIVE AND POSSIBLY STEROID ANTI-INFLAMMATORY
FR2911781B1 (en) * 2007-01-26 2009-03-20 Fabre Pierre Dermo Cosmetique DERMATOLOGICAL EMULSION AND PREPARATION METHOD
EP1970049A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D and corticosteroid
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition

Also Published As

Publication number Publication date
EP2515912A1 (en) 2012-10-31
CA2785249A1 (en) 2011-06-30
WO2011076206A1 (en) 2011-06-30
JP5548275B2 (en) 2014-07-16
EP2515912A4 (en) 2013-12-25
HK1177695A1 (en) 2013-08-30
CN102770143A (en) 2012-11-07
JP2013515017A (en) 2013-05-02
AU2009357263B2 (en) 2015-04-09
IL220513A0 (en) 2012-08-30
ZA201204619B (en) 2013-09-25
IL220513A (en) 2016-05-31
BR112012015447A2 (en) 2016-03-15
MX2012007227A (en) 2012-07-30
CN102770143B (en) 2014-11-05
RU2500387C1 (en) 2013-12-10
AU2009357263A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
NZ601002A (en) Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
MX2016013693A (en) Transdermal cream.
ECSP13012715A (en) METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS WITH IBP CONTENT
CL2013002550A1 (en) A highly concentrated stable liquid subcutaneous injectable pharmaceutical formulation of a pharmaceutically active anti-her2 antibody consisting essentially of trastuzumab; his / hci a stabilizing agent and a non-ionic surfactant; kit and its use to treat diseases such as cancer (divisional application No. 0269-2012).
MX2018008012A (en) Hair growth composition and method.
EA201290596A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ONE OR MORE ETHERS OF FUMAR ACID IN A DECOMPATED MATRIX
MX363379B (en) Stabilized topical formulations containing core-shell microcapsules.
MX2015002239A (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions.
GB2459809A (en) Fatty acid formulations and methods of use thereof
PE20142367A1 (en) IMIQUIMOD FORMULATIONS
MX346961B (en) Pharmaceutical formulations containing corticosteroids for topical administration.
CL2013003144A1 (en) Composition comprising a) fermented rice extract with monascus purpureus, b) an omega fatty acid, c) l-carnitine and one or more of the following: d) at least one policosanol, e) resveratrol, f) coenzyme q10 and g) At least one vitamin, useful as anticolesterolemic and antitriglyceridemic and to increase HDL cholesterol.
AR082124A1 (en) PROCESS TO PURIFY AN ALKYL ESTER OF A FAT ACID THROUGH A LIQUID / LIQUID EXTRACTION
NZ603828A (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012071389A3 (en) Stable cannabinoid compositions and methods for making and storing them
MX364687B (en) O/w microemulsion composition.
IN2015DN02707A (en)
MX2017010716A (en) Millicapsule formulations comprising polyunsaturated free fatty acids.
IN2015DN04096A (en)
MX2014001065A (en) New (trimethoxyphenylamino)pyrimidinyl formulations.
WO2012108748A3 (en) Composition and cosmetic composition for treating brain cancer comprising albizzia julibrissin extract
NZ596429A (en) Oil-in-water emulsion of mometasone and propylene glycol
CR20150320A (en) PHARMACEUTICAL FORMULATION OF N- [5- [2- (3,5-DIMETOXIFENIL) ETIL] -H-PIRAZOL-3-IL] -4 - [(3R, 5S) -3,5-DIMETHYLIPIPERAZIN-1-IL] BENZAMIDA
WO2014205109A3 (en) Compositions and methods for the treatment and management of steatosis in human liver

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 DEC 2016 BY AJ PARK

Effective date: 20150311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2017 BY COMPUTER PACKAGES INC

Effective date: 20161201

LAPS Patent lapsed